Financial Review: Electromed (NYSE:ELMD) & Endonovo Therapeutics (OTCMKTS:ENDV)

Electromed (NYSE:ELMDGet Free Report) and Endonovo Therapeutics (OTCMKTS:ENDVGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares Electromed and Endonovo Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Electromed $48.07 million 1.82 $3.17 million $0.37 27.54
Endonovo Therapeutics $140,000.00 4.78 -$18.48 million N/A N/A

Electromed has higher revenue and earnings than Endonovo Therapeutics.

Profitability

This table compares Electromed and Endonovo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Electromed 6.51% 8.78% 7.44%
Endonovo Therapeutics -1,717.21% N/A -408.63%

Insider & Institutional Ownership

26.7% of Electromed shares are held by institutional investors. 12.7% of Electromed shares are held by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Electromed and Endonovo Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electromed 0 0 2 0 3.00
Endonovo Therapeutics 0 0 0 0 N/A

Electromed presently has a consensus price target of $20.50, indicating a potential upside of 101.18%. Given Electromed’s higher possible upside, analysts clearly believe Electromed is more favorable than Endonovo Therapeutics.

Risk & Volatility

Electromed has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500.

Summary

Electromed beats Endonovo Therapeutics on 10 of the 11 factors compared between the two stocks.

About Electromed

(Get Free Report)

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care and institutional markets for patients with bronchiectasis, cystic fibrosis, and neuromuscular diseases. It markets its products primarily to physicians and health care providers, as well as directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

About Endonovo Therapeutics

(Get Free Report)

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Receive News & Ratings for Electromed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed and related companies with MarketBeat.com's FREE daily email newsletter.